SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 3 filers reported holding SYROS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $0 | -100.0% | 140 | -63.6% | 0.00% | – |
| Q4 2021 | $1,000 | -99.6% | 385 | -99.1% | 0.00% | – |
| Q3 2021 | $255,000 | +3.2% | 45,117 | -0.5% | 0.00% | – |
| Q2 2021 | $247,000 | +43.6% | 45,358 | +96.7% | 0.00% | – |
| Q1 2021 | $172,000 | +561.5% | 23,054 | +856.6% | 0.00% | – |
| Q4 2020 | $26,000 | – | 2,410 | +2670.1% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 87 | -85.0% | 0.00% | – |
| Q3 2019 | $6,000 | 0.0% | 580 | -18.3% | 0.00% | – |
| Q2 2019 | $6,000 | +50.0% | 710 | +36.8% | 0.00% | – |
| Q1 2019 | $4,000 | -20.0% | 519 | -51.4% | 0.00% | – |
| Q4 2018 | $5,000 | -72.2% | 1,068 | -31.4% | 0.00% | – |
| Q3 2018 | $18,000 | +100.0% | 1,557 | +68.1% | 0.00% | – |
| Q2 2018 | $9,000 | -71.0% | 926 | -62.2% | 0.00% | -100.0% |
| Q1 2018 | $31,000 | -73.0% | 2,449 | -79.3% | 0.00% | -80.0% |
| Q4 2017 | $115,000 | – | 11,837 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,439,895 | $18,747,000 | 4.66% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $31,528,000 | 2.07% |
| Omega Fund Management, LLC | 2,274,831 | $12,398,000 | 1.40% |
| Altium Capital Management LP | 1,076,942 | $5,869,000 | 1.36% |
| Samsara BioCapital, LLC | 2,189,199 | $10,599,000 | 1.31% |
| Sio Capital Management, LLC | 800,000 | $4,360,000 | 1.08% |
| Flagship Pioneering Inc. | 2,938,494 | $16,015,000 | 0.20% |
| EcoR1 Capital, LLC | 1,000,000 | $5,450,000 | 0.20% |
| Artal Group S.A. | 1,700,000 | $9,265,000 | 0.19% |
| ACT CAPITAL MANAGEMENT, LLC | 52,500 | $287,000 | 0.15% |